Purinergic Receptor (Purinoceptor) Antagonists Drug Pipeline Market Research Report 2022 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

This "Purinergic Receptor (Purinoceptor) Antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Purinergic Receptor (Purinoceptor) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Purinergic Receptor (Purinoceptor) Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Purinergic Receptor (Purinoceptor) Antagonists.

Purinergic Receptor (Purinoceptor) Antagonists Emerging Drugs Chapters

This segment of the Purinergic Receptor (Purinoceptor) Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Purinergic Receptor (Purinoceptor) Antagonists Emerging Drugs

Gefapixant: Merck & Co

Gefapixant, an investigational, orally administered, selective Purinergic P2X3 receptor antagonist, for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults. In March 2021, Merck known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for gefapixant.

Selatogrel: Idorsia Pharmaceuticals

Selatogrel acts as P2Y12 receptor antagonist, it is administered subcutaneously. It is being developed by Antares Pharma in partnership with Idorsia Pharmaceuticals for the treatment of myocardial infarction using Antare's Quickshot auto-injector. It is currently in Phase III stage of development.

Purinergic Receptor (Purinoceptor) Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Purinergic Receptor (Purinoceptor) Antagonists drugs segregated based on following parameters that define the scope of the report.

Major Players in Purinergic Receptor (Purinoceptor) Antagonists

There are approx. 40+ key companies which are developing the therapies for Purinergic Receptor (Purinoceptor) Antagonists. The companies which have their Purinergic Receptor (Purinoceptor) Antagonists drug candidates in the most advanced stage, i.e. Pre-registration include, Merck & Co.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Purinergic Receptor (Purinoceptor) Antagonists drugs.

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Purinergic Receptor (Purinoceptor) Antagonists drugs?
• How many Purinergic Receptor (Purinoceptor) Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Purinergic Receptor (Purinoceptor) Antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Purinergic Receptor (Purinoceptor) Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Purinergic Receptor (Purinoceptor) Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Incyte Corporation
• Arcus Biosciences
• Corvus Pharmaceuticals
• Idorsia Pharmaceuticals
• Tarus Therapeutics
• Dizal Pharmaceutical
• Corvus Pharmaceuticals

Key Products

• INCB-106385
• Etrumadenant
• Ciforadenant
• Selatogrel
• TT-4
• TT-10
• DZD-2269
• Ciforadenant

Key Topics Covered:

Introduction

Executive Summary

Purinergic Receptor (Purinoceptor) Antagonists: Overview

• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

• Comparative Analysis

Selatogrel: Idorsia Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Etrumadenant: Arcus Biosciences

• Product Description
• Research and Development
• Product Development Activities

Early stage products (Phase I)

• Comparative Analysis

DZD-2269: Dizal Pharmaceutical

• Product Description
• Research and Development
• Product Development Activities

Preclinical stage products

• Comparative Analysis

Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Purinergic Receptor (Purinoceptor) Antagonists Key Companies

Purinergic Receptor (Purinoceptor) Antagonists Key Products

Purinergic Receptor (Purinoceptor) Antagonists- Unmet Needs

Purinergic Receptor (Purinoceptor) Antagonists- Market Drivers and Barriers

Appendix

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/b1e0fi

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900